NCT05747677View on ClinicalTrials.gov

A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

February 6, 2023

Study Completion Date

February 6, 2023

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
DRUG

HH-120 Nasal Spray

HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.

Trial Locations (1)

100015

Beijing Ditan Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Ditan Hospital

OTHER